EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Concentrations of ceftazidime and avibactam in bile fluid—a prospective phase IIb study

Andrea Witowski, Lars Palmowski, Iris K Minichmayr, Markus Zeitlinger, Christoph Dorn, Constantin Lier, Michael Adamzik, Hartmuth Nowak, Tim Rahmel

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae361 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Andrea Witowski und 8 weiteren Autor:innen. Beteiligte Einrichtung: Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, D-44892 Bochum, Germany. Hauptthemen laut MEDLINE: Bile, Azabicyclo Compounds, Ceftazidime, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The rise in carbapenem-resistant bacteria and the limited number of effective antibiotics pose a major health-care threat. The combination of ceftazidime (CAZ) and avibactam (AVI) represents an approved treatment option for carbapenem-resistant intra-abdominal infections. However, data on the pharmacokinetic profile of AVI in the hepatobiliary compartment is lacking.

Objectives

To provide clinical in vivo data on the concentration of AVI in bile fluid as a surrogate for hepatobiliary excretion.

Methods

A single dose of 2000/500 mg CAZ/AVI was administered prolonged over 2 h to 10 patients prior to abdominal surgery, with bile samples available in nine patients in this phase IIb study (DRKS-ID: DRKS00023533). Antibiotic concentrations in plasma (0–8 h), bile (after resection) and pharmacodynamic parameters were determined.

Results

The mean concentration across individuals in bile was 33.5 mg/L (±20.5 mg/L) for CAZ and 7.1 mg/L (±3.5 mg/L) for AVI, resulting in bile/plasma ratios of 0.58 (±0.26) and 0.61 (±0.18). The Cmax in plasma was 87.2 mg/L (±25.0 mg/L) for CAZ and 18.6 mg/L (±6.29 mg/L) for AVI, with AUC0−∞ values of 351 h·mg/L (±104 h·mg/L) and 72.1 h·mg/L (±32.1 h·mg/L), respectively. Plasma concentrations of both CAZ and AVI remained more than 50% of the dosing interval above the minimum inhibitory concentrations (T>MIC > 50%; MICCAZ = 8 mg/L, MICAVI = 1 mg/L) in all patients. No antibiotic-associated side effects were reported during the 30-day follow-up.

Conclusions

The concentrations of CAZ and AVI in bile suggest their potential as a valuable therapeutic option for multi-resistant biliary infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BileAzabicyclo CompoundsCeftazidimeAnti-Bacterial AgentsMicrobial Sensitivity TestsHumansMaleMiddle AgedFemaleProspective StudiesAgedAdultAged, 80 and overIntraabdominal InfectionsDrug Combinations

Substanzen

Azabicyclo CompoundsCeftazidimeAnti-Bacterial AgentsavibactamDrug Combinations

Autor:innen und Institutionen

  • Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, D-44892 Bochum, Germany.
  • Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
  • Institute of Pharmacy, University of Regensburg, Regensburg, Germany.
  • Zentrum für Künstliche Intelligenz, Medizininformatik und Datenwissenschaften, Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany.

Förderung

  • Pfizer

Zitieren

APA

Witowski, A., Palmowski, L., Minichmayr, I. K., Zeitlinger, M., Dorn, C., Lier, C., Adamzik, M., Nowak, H., & Rahmel, T. (2024). Concentrations of ceftazidime and avibactam in bile fluid—a prospective phase IIb study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae361

Vancouver

Witowski A, Palmowski L, Minichmayr IK, Zeitlinger M, Dorn C, Lier C, et al. Concentrations of ceftazidime and avibactam in bile fluid—a prospective phase IIb study. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae361

BibTeX
@article{Witowski2024,
  author = {Witowski, Andrea and Palmowski, Lars and Minichmayr, Iris K and Zeitlinger, Markus and Dorn, Christoph and Lier, Constantin and Adamzik, Michael and Nowak, Hartmuth and Rahmel, Tim},
  title = {Concentrations of ceftazidime and avibactam in bile fluid—a prospective phase IIb study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae361}
}
Kostenlos starten →